Avantor (AVTR)
(Delayed Data from NYSE)
$25.53 USD
+0.46 (1.83%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $25.54 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Brokerage Reports
Avantor, Inc. [AVTR]
Reports for Purchase
Showing records 41 - 60 ( 134 total )
Company: Avantor, Inc.
Industry: Medical Services
4Q22 Beats; Bioprocess Business Driving LT Growth and FY23 Guidance
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
4Q22 Earnings and FY23 Guidance, Mostly Beating Expectations with BioProcess Driving Upside
Provider: KeyBanc Capital Markets
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Provider: Zacks Investment Research
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Positive Announcements Rolling Out at JPM
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Life Science Technology - Biologic Transformation Continues - 2023 Outlook
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Provider: Zacks Investment Research
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Provider: Zacks Investment Research
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
3Q22 - 4Q Lower, but BioProcess LT Growth Driver
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Life Science Bioproduction Update 2022: Three Segments Emerging as Washington Support Indicates Long Horizon
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Model Reboot - Bioprocess, Manufacturing, and Balance Sheet Can Expand Multiple
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Life Sciences: COVID Era Concluding - Mapping Company Exposure
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Company: Avantor, Inc.
Industry: Medical Services
Bioprocess Strong, FX and COVID Detract in 2Q22
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
DHR & SRT3: Strong Life Science Earnings Season Begins
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
2Q Preview - Mapping COVID Sales; 2023 Visibility Increasing
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Avantor, Inc.
Industry: Medical Services
Ireland Bioprocess Tour Recap: Growth Not Slowing
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department